Arcutis Biotherapeutics
ARQT
56 hedge funds and large institutions have $1.02B invested in Arcutis Biotherapeutics in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
12% more funds holding
Funds holding: 50 → 56 (+6)
2.7% more ownership
Funds ownership: 85.82% → 88.51% (+2.7%)
5% more capital invested
Capital invested by funds: $974M → $1.02B (+$47.3M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.84M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.28M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.66M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.5M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$1.23M |
| 3 |
Goldman Sachs
New York
|
-$801K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$668K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$650K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $48K | +$9.31K | +322 | +26% |
|
52
Canada Life
Winnipeg,
Manitoba, Canada
| $37K | +$35.2K | +1,218 | New |
|
|
AIP
53
Ameritas Investment Partners
Lincoln,
Nebraska
| $27K | – | – | – |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| $22K | +$21.8K | +754 | New |
|
55
Osaic Holdings
Scottsdale,
Arizona
| $12K | – | – | – |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$15.6K | -540 | -97% |
|
|
MWNA
57
Marshall Wace North America
New York
| – | -$1.23M | -41,315 | Closed |
|
|
CCM
58
CAAS Capital Management
New York
| – | -$668K | -22,413 | Closed |
|
59
Victory Capital Management
San Antonio,
Texas
| – | -$230K | -7,720 | Closed |
|
|
SO
60
STRS Ohio
Columbus,
Ohio
| – | -$80K | -2,700 | Closed |
|
ARQT Hedge Fund Activity: Q2 2020 in Review
56 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2020, worth a combined $1.02B — up 4.9% from $974M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ARQT positions and 5 closed out — a net gain of 6 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $20.3M. The largest seller was Vivo Capital, cutting an estimated $11.5M.
- 56 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2020, up from 50 in Q1 2020.
- Funds reported $1.02B of Arcutis Biotherapeutics stock for Q2 2020, up 4.9% quarter-over-quarter.
- 11 funds opened new Arcutis Biotherapeutics positions in Q2 2020 and 5 closed out, a net change of +6 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2020 was BlackRock, an estimated $20.3M added.
- The largest Arcutis Biotherapeutics seller in Q2 2020 was Vivo Capital, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2020.